Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)

Polycystic Kidney Disease Clinical Trial

Official title: Randomized, Controlled Pilot Study of Niacinamide in Polycystic Kidney Disease

Status Completed

Clinical Trial Summary

The purpose of this study is to observe the effects of niacinamide on markers of kidney injury, inflammation, kidney cyst growth and kidney function.

Clinical Trial Description

Polycystic Kidney Disease (PKD) is a genetic disease that affects about 1 in 500 people worldwide. It can lead to kidney failure which can lead to death. PKD causes the development of kidney cysts (fluid-filled balloons), which cause worsening kidney function. It is common for people with PKD to also have blood in the urine, kidney pain, high blood pressure, kidney stones, kidney infections, and cysts in the brain or other parts of the body.

There is currently no treatment known to stop cyst growth or a cure for the disease.

Participants in this study will be randomly assigned to one of two groups: niacinamide or placebo. Participants have an equal chance of being assigned to either of the groups. For people that qualify and decide to participate in this study, they will be asked to make five visits to the study clinic and complete two study related phone calls over the course of 12 months. ;

Related Conditions & MeSH terms

• Kidney Diseases
• Polycystic Kidney Disease
• Polycystic Kidney Diseases

• NCT number: NCT02558595
• Study type: Interventional
• Source: University of Kansas Medical Center
• Status: Completed
• Phase: Phase 2
• Start date: September 22, 2015
• Completion date: December 18, 2017